Loading organizations...
Grove Biopharma develops novel therapeutics through its Bionic Biologics™ platform, a synthetic modality engineered to target intracellular protein-protein interactions. This platform leverages hybrid biomolecules integrating biologic and synthetic design for enhanced functionality and cell permeability. These customizable protein-like polymers disrupt or degrade disease-causing target proteins inside cells.
Founded in 2020, Grove Biopharma originated from the innovative work of Nathan Gianneschi, inventor of its protein-like polymer technology. The company was conceived from the insight that many severe human diseases stem from dysregulated intracellular protein-protein interactions, often unreachable by traditional therapies. Geoffrey M. Duyk, M.D., Ph.D. leads as CEO, guiding this novel approach.
Grove Biopharma aims to deliver improved treatment options for patients with conditions including cancer, neurodegenerative diseases, and rare disorders. The company’s vision centers on providing precision, protein-scale solutions to complex biological problems. By deploying its Bionic Biologics to modulate intracellular pathways, Grove Biopharma is committed to advancing transformative new medicines.
Groove Biopharma has raised $10.0M across 2 funding rounds.
Groove Biopharma has raised $10.0M in total across 2 funding rounds.
Grove Biopharma is a biotechnology company developing Bionic Biologics™, a novel class of synthetic biomolecules that penetrate cells to target intracellular protein-protein interactions (PPIs) previously undruggable by traditional therapies[2][4][5]. These hybrid molecules integrate biologic and synthetic design principles for higher potency, modularity, and cell permeability, addressing diseases like cancer, neurodegenerative disorders, and rare conditions by disrupting disease-causing proteins such as AR-V7 in prostate cancer, SHOC2, MYC interactions, tau pathology, and Keap1-Nrf2[4][5]. The company serves patients with hard-to-treat diseases, solving the core problem of limited modalities that can't access intracellular targets, and demonstrates growth momentum through a $30 million Series A funding round, incubation by Portal Innovations, and participation in events like the ACS Fall 2025 Materials Biology Symposium[4][5].
Based in Chicago, Grove operates as a multidisciplinary team of chemists, biologists, materials scientists, and entrepreneurs, leveraging technology pioneered at Northwestern University to contribute to the local life sciences ecosystem[2][4][5].
Grove Biopharma was co-founded in 2020 by scientific founder Nathan Gianneschi, a Northwestern University professor who developed the core Bionic Biologics platform, alongside CEO Geoffrey Duyk and chief technology officer Paul Bertin[2][4][5]. The idea emerged from Gianneschi's research flipping traditional views: using synthetic materials not just as delivery vehicles but as the therapeutic agents themselves to target intracellular PPIs, incubated amid the pandemic by local investor Portal Innovations in Chicago's West Loop, co-located with the Chan Zuckerberg Biohub[5].
(Note: Some older records reference a "Groove Biopharma" founded in 2008 focused on microRNA therapeutics, but current operations align with Grove Biopharma's 2020 launch and miRNA-like synthetic biologics[1][3][5].) Early traction included weathering fundraising challenges to secure $30 million in Series A funding after over a year of effort, proving the platform's potential for a new drug development paradigm[5].
Grove rides the synthetic biology and advanced materials trend in biotech, where materials science redefines therapeutics to conquer the "undruggable" proteome—80% of disease drivers involving intracellular PPIs[4][5]. Timing aligns with surging demand for next-gen modalities post-mRNA vaccine successes, amid a Chicago life sciences boom fueled by hubs like CZ Biohub and Portal Innovations[2][4][5]. Market forces favoring Grove include investor appetite for platform companies ($30M Series A despite headwinds) and unmet needs in oncology/neurodegeneration, where biologics dominate extracellular targets but falter inside cells[5]. By pioneering "material-as-drug," Grove influences the ecosystem, potentially unlocking new fields like polymer-based intracellular therapies and boosting regional biotech density[4][5].
Grove Biopharma is poised to advance its lead prostate cancer program targeting AR-V7 toward first-in-human trials, likely requiring additional funding, while expanding oncology (SHOC2, MYC) and neurodegeneration pipelines[5]. Trends like AI-driven drug design, multimodal delivery innovations, and precision medicine will accelerate its modular platform, evolving Grove from Chicago upstart to category leader in bionic therapeutics. As it scales proof-of-concept to clinic, expect broader ecosystem impact through partnerships and talent influx, fulfilling its promise of protein-scale solutions for patients long underserved by current options—transforming synthetic design into the next biologic revolution[4][5].
Groove Biopharma has raised $10.0M in total across 2 funding rounds.
Groove Biopharma's investors include Versant Ventures, Alexandria Venture Investments, ARCH Venture Partners, Carl Weissman, WRF Capital.
Groove Biopharma has raised $10.0M across 2 funding rounds. Most recently, it raised $6.0M Series B in December 2011.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2011 | $6.0M Series B | Versant Ventures, Alexandria Venture Investments, ARCH Venture Partners, Carl Weissman, WRF Capital | |
| Apr 1, 2010 | $4.0M Series A | Versant Ventures |